Bristol-Myers Squibb
Affiliations
In 2007 Bristol-Myers Squibb (BMS) announced collaboration with Isis Pharmaceuticals Inc. in the development of cardiovascular disease treatment[1].
2007 also saw BMS enter in partnership with Pfizer for a worldwide collaboration to develop and commercialize apixaban (an anticoagulant for the prevention and treatment of a broad range of venous and arterial thrombotic conditions). BMS also reports that 'in a separate agreement, the companies will also collaborate on the research, development and commercialization of a Pfizer discovery program which includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes'.[2]
In February 2007, Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus Therapeutics announced a worldwide strategic alliance to discover, develop and commercialize Adnectin-based therapeutics for oncology-related targets[3].
- 'Under the terms of the agreement, Bristol-Myers Squibb will provide committed funds of approximately $30 million over the next three years to Adnexus... Adnexus also is eligible to receive regulatory milestone payments of up to $210 million per product, as well as royalties on product sales and sales-based milestone payments'.
References
- ↑ BMS Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals Accessed 16th December 2007
- ↑ BMS Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds Accessed 16th December 2007
- ↑ BMS Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds Accessed 16th December 2007
